MA33552B1 - Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques - Google Patents

Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques

Info

Publication number
MA33552B1
MA33552B1 MA34459A MA34459A MA33552B1 MA 33552 B1 MA33552 B1 MA 33552B1 MA 34459 A MA34459 A MA 34459A MA 34459 A MA34459 A MA 34459A MA 33552 B1 MA33552 B1 MA 33552B1
Authority
MA
Morocco
Prior art keywords
spiro
enantiomers
therapeutic agents
oxindole compounds
enantiomer
Prior art date
Application number
MA34459A
Other languages
Arabic (ar)
English (en)
Inventor
Mikhail Chafeev
Jianmin Fu
Jean-Jacques Cadieux
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42416878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33552(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MA33552B1 publication Critical patent/MA33552B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'énantiomère (S) du composé de formule (I) ou un solvate pharmaceutiquement acceptable ou un promédicament de celui-ci. Cet énantiomère (S) est utile pour le traitement de maladies ou affections, telles que la douleur, qui sont atténuées ou soulagées par la modulation de canaux sodiques sensibles au voltage.
MA34459A 2009-06-29 2011-12-16 Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques MA33552B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22142409P 2009-06-29 2009-06-29
PCT/US2010/040187 WO2011002708A1 (fr) 2009-06-29 2010-06-28 Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques

Publications (1)

Publication Number Publication Date
MA33552B1 true MA33552B1 (fr) 2012-09-01

Family

ID=42416878

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34459A MA33552B1 (fr) 2009-06-29 2011-12-16 Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques

Country Status (34)

Country Link
US (4) US8450358B2 (fr)
EP (3) EP3156407A1 (fr)
JP (3) JP2012532107A (fr)
KR (1) KR101751378B1 (fr)
CN (2) CN102471347B (fr)
AR (1) AR077252A1 (fr)
AU (1) AU2010266549B2 (fr)
BR (1) BRPI1012129A2 (fr)
CA (1) CA2764878C (fr)
CL (1) CL2011003335A1 (fr)
CO (1) CO6470866A2 (fr)
CY (1) CY1117776T1 (fr)
DK (1) DK2448943T3 (fr)
EC (1) ECSP11011512A (fr)
ES (2) ES2578779T3 (fr)
HR (2) HRP20110946A2 (fr)
HU (1) HUE029658T2 (fr)
IL (3) IL217285A (fr)
MA (1) MA33552B1 (fr)
MX (2) MX342298B (fr)
MY (1) MY159099A (fr)
NZ (1) NZ596903A (fr)
PE (2) PE20160216A1 (fr)
PH (2) PH12011502619A1 (fr)
PL (2) PL2789617T3 (fr)
PT (1) PT2448943T (fr)
RU (1) RU2535667C2 (fr)
SG (1) SG176307A1 (fr)
SI (1) SI2448943T1 (fr)
SM (1) SMT201600203B (fr)
TN (1) TN2011000664A1 (fr)
TW (1) TWI465452B (fr)
WO (1) WO2011002708A1 (fr)
ZA (1) ZA201108960B (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278088B2 (en) 2002-02-19 2016-03-08 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY158766A (en) * 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
RU2009117642A (ru) 2006-10-12 2010-11-20 Ксенон Фармасьютикалз Инк. (Ca) Применение спирооксиндоловых соединений в качестве терапевтических средств
HRP20150882T1 (hr) * 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
US8101647B2 (en) * 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CN104945420A (zh) 2009-06-29 2015-09-30 因塞特公司 作为pi3k抑制剂的嘧啶酮类
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
NZ599334A (en) * 2009-10-14 2014-03-28 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
WO2011047173A2 (fr) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Compositions pharmaceutiques à usage oral
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
CN102946859B (zh) 2010-02-26 2016-03-02 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
WO2011130342A1 (fr) 2010-04-14 2011-10-20 Incyte Corporation Dérivés condensés en tant qu'inhibiteurs de ρi3κδ
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012049555A1 (fr) 2010-10-13 2012-04-19 Lupin Limited Composés spirocycliques en tant que modulateurs de canaux sodiques dépendants du voltage
CA2822070C (fr) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(phenyl substitue)ethyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
AR087760A1 (es) 2011-09-02 2014-04-16 Incyte Corp Heterociclilaminas como inhibidores de pi3k
EP2638908A1 (fr) * 2012-03-16 2013-09-18 Phytotox SpA Poison paralysant de mollusque
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
KR20150002794A (ko) * 2012-04-12 2015-01-07 제논 파마슈티칼스 인크. 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성
GB201209015D0 (en) * 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
EP2956118A1 (fr) * 2013-02-13 2015-12-23 Novartis AG Agents analgésiques oculaires topiques
DK3080134T3 (en) 2013-12-13 2018-10-22 Vertex Pharma PRODRUGS OF PYRIDONAMIDS USED AS MODULATORS OF SODIUM CHANNELS
US20150216794A1 (en) * 2014-02-05 2015-08-06 IVAX International GmbH Methods of treating pain associated with osteoarthritis of a joint with a topical formulation of a spiro-oxindole compound
EP3126360A1 (fr) 2014-03-29 2017-02-08 Lupin Limited Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2016109795A1 (fr) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Funapide et difluorofunapide deutérés
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
PT3831833T (pt) 2015-02-27 2023-02-06 Incyte Corp Processos para a preparação de um inibidor pi3k
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183060A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Procédé de synthèse d'un inhibiteur de phospho-inositide 3-kinases
US9840513B2 (en) * 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
TW201722938A (zh) 2015-09-04 2017-07-01 魯賓有限公司 作為電位閘控鈉通道調節子之磺醯胺化合物
JP6572392B2 (ja) 2015-12-18 2019-09-11 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 電位作動型ナトリウムチャネルにおいて選択的活性を有する、ヒドロキシアルキルアミンおよびヒドロキシシクロアルキルアミンで置換されたジアミン−アリールスルホンアミド化合物
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
CN114409665A (zh) 2016-06-16 2022-04-29 泽农医药公司 螺-吲哚酮化合物的固态形式
WO2018163077A1 (fr) 2017-03-08 2018-09-13 Lupin Limited Composés indanyle utilisés en tant que modulateurs de canaux sodiques dépendant de la tension
EP3592747A1 (fr) 2017-03-10 2020-01-15 Council of Scientific and Industrial Research Composés de spirooxindole en tant qu'inhibiteurs de gsk3 et leur procédé de préparation
EP3625214B1 (fr) 2017-05-16 2022-07-06 Vertex Pharmaceuticals Incorporated Amides de pyridone deutérés et leurs promédicaments utilisés en tant que modulateurs de canaux sodiques
BR112020000553A2 (pt) 2017-07-11 2020-07-21 Vertex Pharmaceuticals Incorporated carboxamidas como moduladores de canal de sódio
SG11202002707VA (en) 2017-10-10 2020-04-29 Biogen Inc Process for preparing spiro derivatives
US20190343817A1 (en) 2018-02-12 2019-11-14 Vertex Pharmaceuticals Incorporated Method of treating pain
KR102884803B1 (ko) 2018-06-01 2025-11-12 인사이트 코포레이션 Pi3k 관련 장애의 치료를 위한 투여 요법
EP3820860B1 (fr) 2018-07-09 2025-10-15 Lieber Institute, Inc. Composés pyridazineg pour inhiber nav1.8
CA3105657A1 (fr) 2018-07-09 2020-01-16 Lieber Institute, Inc. Composes de pyridine carboxamide pour inhiber nav1.8
PL3851436T3 (pl) 2018-09-10 2024-12-16 Kaken Pharmaceutical Co., Ltd. Nowa heteroaromatyczna pochodna amidowa i lek ją zawierający
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (fr) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters et carbamates utilisés en tant que modulateurs de canaux sodiques
WO2020163242A1 (fr) 2019-02-05 2020-08-13 Magnetic Variation Services, Llc Procédés et systèmes de géoguidage pour des performances de forage améliorées
CA3121861A1 (fr) 2019-02-05 2020-08-13 Motive Drilling Technologies, Inc. Affichage de fond de trou
WO2020176763A1 (fr) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Forme posologique comprenant un promédicament inhibiteur de canal sodique na 1,8
WO2020219867A1 (fr) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Compositions de co-cristaux d'amide de pyridone pour le traitement de la douleur
JP2022547532A (ja) 2019-09-09 2022-11-14 パシラ・セラピューティクス・インコーポレイテッド ナトリウムチャネルブロッカーを含む徐放性熱硬化性ゲルおよびそれを製造する方法
AU2020397059A1 (en) 2019-12-06 2022-07-21 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
WO2022192427A1 (fr) 2021-03-10 2022-09-15 Pacira Therapeutics, Inc. Gels thermodurcissables à libération prolongée comprenant des bloqueurs de canaux sodiques et leurs méthodes de fabrication
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
IL308954A (en) 2021-06-04 2024-01-01 Vertex Pharma Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
US20240368135A1 (en) 2021-06-04 2024-11-07 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
AU2022286511A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
US20240400544A1 (en) 2021-06-04 2024-12-05 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
RU2763140C1 (ru) * 2021-06-29 2021-12-27 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) 4-[2-(гидроксиметил)-фениламино]-6',6'-диметил-1'-(2-фторфенил)-3-(4-хлорбензоил)-6',7'-дигидро-5Н-спиро[фуран-2,3'-индол]-2',4',5(1'H,5'H)-трион в качестве средства, обладающего противомикробной активностью
EP4511116A1 (fr) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Composés hétéroaryles pour le traitement de la douleur
CN119522214A (zh) 2022-04-22 2025-02-25 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
US20250388543A1 (en) 2022-04-22 2025-12-25 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
JP2025513452A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
JP2026501116A (ja) 2022-12-06 2026-01-14 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの置換テトラヒドロフラン調節因子の合成のための製造方法
AU2024306684A1 (en) * 2023-06-28 2025-08-07 Avelos Therapeutics Inc. Substituted spiro compound derivatives and their pharmaceutical use
WO2025090511A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Procédés de préparation de modulateurs de canaux sodiques et formes solides de ceux-ci pour le traitement de la douleur
WO2025090480A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Composés hétéroaryles pour le traitement de la douleur
WO2025090516A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Procédés de préparation de composés pour le traitement de la douleur et de formes solides de ceux-ci
WO2025090465A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Composés hétéroaryle pour le traitement de la douleur
WO2025122953A1 (fr) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Schémas posologiques et formulations de suzétrigine pour le traitement des douleurs sévères et chroniques
WO2026006674A1 (fr) 2024-06-28 2026-01-02 Vertex Pharmaceuticals Incorporated Composés hétéroaryle pour le traitement de la douleur
WO2026013449A2 (fr) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Composés dérivés d'oxazolidone et leur utilisation dans le traitement de la douleur chronique et aiguë

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3189617A (en) 1961-02-03 1965-06-15 Sterling Drug Inc 1-aryloxindoles and their preparation
DE1956237A1 (de) 1969-11-08 1971-05-13 Basf Ag Spiro-pyrrolizidon-oxindole
DE2113343A1 (de) 1971-03-19 1972-09-21 Thiemann Chem Pharm Fab Indolo[2,3-b] chinolone und Verfahren zu ihrer Herstellung
US3723459A (en) 1971-04-23 1973-03-27 Mc Neil Labor Inc 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
CH577461A5 (fr) 1975-08-13 1976-07-15 Robins Co Inc A H
US4670566A (en) 1979-07-12 1987-06-02 A. H. Robins Company, Incorporated 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4440785A (en) 1980-10-30 1984-04-03 A. H. Robins Company, Inc. Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation
US4438130A (en) 1981-11-12 1984-03-20 The Upjohn Company Analgesic 1-oxa-, aza- and thia-spirocyclic compounds
JPS60142984A (ja) 1983-12-28 1985-07-29 Kyorin Pharmaceut Co Ltd 新規なスピロピロリジン−２，５−ジオン誘導体およびその製造法
US4569942A (en) 1984-05-04 1986-02-11 Pfizer Inc. N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents
JPS6130554A (ja) 1984-07-23 1986-02-12 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤
US4690943A (en) 1984-09-19 1987-09-01 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
US4721721A (en) 1984-12-18 1988-01-26 Rorer Pharmaceutical Corporation 6-(4-thiazole) compounds, cardiotonic compositions including the same, and their uses
DE3608088C2 (de) 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
WO1993012786A1 (fr) 1986-07-10 1993-07-08 Howard Harry R Jr Derives d'indolinone
CA1322197C (fr) 1987-07-17 1993-09-14 Bernd Buchmann Derives 9-halogene-(z)-prostaglandine, procede pour leur production et leur utilisation comme agents pharmaceutiques
US5182289A (en) 1988-06-14 1993-01-26 Schering Corporation Heterobicyclic compounds having antiinflammatory activity
DK0429685T3 (da) 1989-07-25 1997-12-15 Taiho Pharmaceutical Co Ltd Oxoindolderivat
DE3932953A1 (de) 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3935514A1 (de) 1989-10-25 1991-05-02 Boehringer Mannheim Gmbh Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5023265A (en) 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5484778C1 (en) 1990-07-17 2001-05-08 Univ Cleveland Hospitals Phthalocynine photosensitizers for photodynamic therapy and methods for their use
AU648359B2 (en) 1990-11-22 1994-04-21 Janssen Pharmaceutica N.V. Isonicotinic acid derivatives
US5116854A (en) 1991-06-28 1992-05-26 Pfizer Inc. Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5686624A (en) 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5314685A (en) 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
WO1994003427A1 (fr) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) et disulfures associes (seleniures) inhibant les tyrosine kinases et presentant des proprietes antitumorales
US5278162A (en) 1992-09-18 1994-01-11 The Du Pont Merck Pharmaceutical Company 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man
US5296478A (en) 1992-10-07 1994-03-22 The Dupont Merck Pharmaceutical Co. 1-substituted oxindoles as cognition enhancers
US5776936A (en) 1992-11-13 1998-07-07 Pharmacia & Upjohn Company Marcfortine/paraherquamide derivatives useful as antiparasitic agents
DE4242451A1 (de) 1992-12-16 1994-06-23 Basf Ag Verfahren zur Herstellung von 5-Ringheterocyclen
US5298522A (en) 1993-01-22 1994-03-29 Pfizer Inc. 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
FR2708606B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
AT400950B (de) 1994-02-04 1996-04-25 Immodal Pharmaka Gmbh Verfahren zur technischen herstellung definierter isomerengemische aus verbindungen mit spirozyklischen - aminocarboxyl- und/oder spirozyklischen - aminocarbonyl-systemen
AU2310895A (en) 1994-04-07 1995-10-30 Cemaf Novel spiro{indole-pyrrolidine} derivatives as melatoninergic agonists, method for preparing same and use thereofas a drug
FR2722195B1 (fr) 1994-07-07 1996-08-23 Adir Nouveaux derives de 1,3-dihydro-2h-pyrrolo(2,3-b) pyridin-2-ones et oxazolo(4,5-b) pyridin-2(3h)-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5618819A (en) 1994-07-07 1997-04-08 Adir Et Compagnie 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds
JPH10510821A (ja) 1994-12-22 1998-10-20 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 四環式スピロ化合物、その製法およびその５ｈｔ１ｄレセプターアンタゴニストとしての使用
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
CA2235686C (fr) 1995-10-24 2007-06-26 Sanofi Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l'ocytocine
HUP9600855A3 (en) 1996-04-03 1998-04-28 Egyt Gyogyszervegyeszeti Gyar Process for producing tenidap
JPH1095766A (ja) 1996-09-19 1998-04-14 Sanwa Kagaku Kenkyusho Co Ltd アセトアミド誘導体、及びその用途
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
EP0989856B1 (fr) 1997-01-20 2010-05-12 IMMODAL PHARMAKA GESELLSCHAFT m.b.H. Procede et substances pour liberer un facteur de croissance issu des cellules endotheliales, facteur de croissance libere selon ce procede, et son utilisation
NO317155B1 (no) 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
PT1008588E (pt) 1997-02-10 2003-09-30 Ono Pharmaceutical Co Derivados da 11,15-o-diaklquil-prostaglandina e processo de producao dos mesmos e farmaco que os contem como ingrediente activo
JP2001524124A (ja) 1997-05-07 2001-11-27 ガレン（ケミカルズ）リミティド テストステロンおよびテストステロン前駆体の投与のための膣内薬物送達用具
WO1999033794A1 (fr) 1997-12-25 1999-07-08 Ono Pharmaceutical Co., Ltd. DERIVES φ-CYCLOALKYLES DE LA PROSTAGLANDINE E¿2?
JP4087938B2 (ja) 1998-02-04 2008-05-21 高砂香料工業株式会社 ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物
EP1422217A3 (fr) 1998-04-01 2004-06-16 Cardiome Pharma Corp. Composés aminocyclohexyle ether et leur utilisation
US20040038970A1 (en) 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
US6235780B1 (en) 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
WO2000006556A1 (fr) 1998-07-27 2000-02-10 Abbott Laboratories Antiproliferants a base d'oxazolines substituees
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
AU770377B2 (en) 1999-05-21 2004-02-19 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
ATE264330T1 (de) 1999-07-21 2004-04-15 Astrazeneca Ab Verbindungen
ES2306665T3 (es) 1999-07-21 2008-11-16 Boehringer Ingelheim Pharmaceuticals Inc. Pequeñas moleculas utiles en el tratamiento de la enfermedad inflamatoria.
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
DE1252330T1 (de) 1999-11-26 2003-11-27 Mcgill University, Montreal Loci der idiopathischen epilepsie, mutationen derselben und verfahren zu deren verwendung zur feststellung, prognose und behandlung von epilepsie
FR2807038B1 (fr) 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
AU2002213204A1 (en) 2000-10-13 2002-04-22 Bristol-Myers Squibb Company Selective maxi-K- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
US6825220B2 (en) 2000-11-10 2004-11-30 Eli Lilly And Company 3-Substituted oxindole β 3 agonists
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US20030078278A1 (en) 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
JP2005507872A (ja) 2001-08-14 2005-03-24 イーライ・リリー・アンド・カンパニー ３−置換オキシインドールβ３アゴニスト
EP1451160B1 (fr) 2001-11-01 2010-01-13 Icagen, Inc. Pyrazole-amides pour utilisation dans le traitement de la douleur
US7244744B2 (en) 2001-11-01 2007-07-17 Icagen, Inc. Piperidines
ES2242890T3 (es) 2001-11-20 2005-11-16 Eli Lilly And Company Agonistas beta 3 de oxindol 3-sustituido.
SE0104341D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New use
WO2003064425A1 (fr) 2002-01-28 2003-08-07 Pfizer Japan Inc. Composes spiropiperidine n-substitues utilises comme ligands pour le recepteur de orl-1
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
US7250442B2 (en) 2002-03-15 2007-07-31 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
JP2005535625A (ja) 2002-06-25 2005-11-24 ワイス 皮膚障害の治療におけるチオオキシインドール誘導体の使用
MXPA04012419A (es) 2002-06-25 2005-04-19 Wyeth Corp Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con la hormona.
US7256218B2 (en) 2002-11-22 2007-08-14 Jacobus Pharmaceutical Company, Inc. Biguanide and dihydrotriazine derivatives
KR20120102571A (ko) * 2003-02-24 2012-09-18 미쓰비시 타나베 파마 코퍼레이션 테나토프라졸의 거울상 이성질체 및 치료를 위한 그 용도
KR20060009938A (ko) 2003-05-16 2006-02-01 화이자 프로덕츠 인코포레이티드 양극성 장애 및 연관된 증상의 치료
CA2525323A1 (fr) 2003-05-16 2004-11-25 Pfizer Products Inc. Procede pour ameliorer les fonctions cognitives en administrant du ziprasidone
CA2525866A1 (fr) 2003-05-16 2004-11-25 Pfizer Products Inc. Traitement de troubles psychotiques et depressifs
WO2004100955A1 (fr) 2003-05-16 2004-11-25 Pfizer Products Inc. Traitements de l'angoisse avec la ziprasidone
PT1651620E (pt) 2003-07-30 2012-02-10 Xenon Pharmaceuticals Inc Derivados de piperizina e sua utilização como agentes terapêuticos
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
WO2005016913A1 (fr) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Composes de tetrahydroisoquinoline ou d'isochroman en tant que ligands du recepteur orl-1 pour le traitement de la douleur et des troubles du systeme nerveux central
WO2005035498A1 (fr) 2003-10-08 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. Utilisation d'un compose bicyclique azote comme agent de regulation alimentaire
EP1557166A1 (fr) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Derives d'alpha-aminoamides pour le traitement des désordres de l'appareil urinaire inférieur
US7507760B2 (en) 2004-01-22 2009-03-24 Neuromed Pharmaceuticals Ltd. N-type calcium channel blockers
GB0406867D0 (en) 2004-03-26 2004-04-28 F2G Ltd Antifungal agents
CA2560796A1 (fr) 2004-03-29 2005-10-20 Merck & Co., Inc. Pyrazinones substituees par biaryle utilisees comme bloquants des canaux sodiques
JP2007530656A (ja) 2004-03-29 2007-11-01 ファイザー株式会社 ＯＲＬ１受容体拮抗薬としてのαアリールまたはヘテロアリールメチルβピペリジノプロパンアミド化合物
WO2005099689A1 (fr) 2004-04-01 2005-10-27 Case Western Reserve University Apport topique de phtalocyanines
GT200500063A (es) 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
US20070299102A1 (en) 2004-04-08 2007-12-27 Topo Target A/S Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer
WO2005104711A2 (fr) 2004-04-27 2005-11-10 Wyeth Purification de modulateurs de recepteur de progesterone
WO2005105753A2 (fr) 2004-05-05 2005-11-10 Unibioscreen S.A. Derives naphthalimides, procedes de fabrication et compositions pharmaceutiques les renfermant
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
CA2566477A1 (fr) 2004-05-14 2005-11-24 Pfizer Products Inc. Derives de pyrimidine destines au traitement de croissance cellulaire anormale
AU2005267331A1 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500183A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
JP4677323B2 (ja) 2004-11-01 2011-04-27 キヤノン株式会社 画像処理装置及び画像処理方法
BRPI0518281A2 (pt) 2004-11-18 2008-11-18 Incyte Corp inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos
DE102005007694A1 (de) 2005-02-18 2006-09-21 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
CA2598690C (fr) 2005-02-22 2011-11-15 The Regents Of The University Of Michigan Inhibiteurs de mdm2, sous forme de petites molecules et utilisations de ces derniers
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY158766A (en) * 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
GT200600179A (es) 2005-04-29 2006-11-22 Proceso para preparar oxindoles y tio-oxindoles 3,3-disustituidos
TW200716632A (en) 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
PL1924264T3 (pl) 2005-09-01 2014-03-31 Hoffmann La Roche Diaminopirymidyny jako modulatory P2X<sub>3</sub> I P2X<sub>2/3</sub>
US7888345B2 (en) 2006-06-09 2011-02-15 Merck Sharp & Dohme Corp. Benzaepinones as sodium channel blockers
WO2008046083A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Utilisation de composés oxindole comme agents thérapeutiques
CA2666136A1 (fr) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Derives spiro-oxindole tricycliques et utilisations de ceux-ci comme agents therapeutiques
WO2008046087A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Composés spiro et leurs utilisations en tant qu'agents thérapeutiques
RU2009117642A (ru) 2006-10-12 2010-11-20 Ксенон Фармасьютикалз Инк. (Ca) Применение спирооксиндоловых соединений в качестве терапевтических средств
US20110294842A9 (en) 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008046082A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Utilisation de composés hétérocycliques comme agents thérapeutiques
WO2008046065A1 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Composés spirohétérocycliques et utilisations de ceux-ci comme agents thérapeutiques
WO2008046084A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et utilisation de ceux-ci comme agents thérapeutiques
GB0704846D0 (en) 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
WO2008117050A1 (fr) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazines pyrazolyl-amino substituées et utilisation de ces composés pour le traitement du cancer
MX2009012834A (es) * 2007-05-29 2010-05-17 Intrexon Corp Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona.
HRP20150882T1 (hr) 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010053998A1 (fr) 2008-11-05 2010-05-14 Xenon Pharmaceuticals, Inc. Dérivés d'indole spiro-condensés utilisables en tant qu'inhibiteurs des canaux sodiques
US20110269788A1 (en) 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
WO2010132352A2 (fr) 2009-05-11 2010-11-18 Xenon Pharmaceuticals Inc. Composés spiro et leur utilisation en tant qu'agents thérapeutiques
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
NZ599334A (en) 2009-10-14 2014-03-28 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
WO2011047173A2 (fr) 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Compositions pharmaceutiques à usage oral
CN102946859B (zh) 2010-02-26 2016-03-02 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
KR20150002794A (ko) 2012-04-12 2015-01-07 제논 파마슈티칼스 인크. 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성

Also Published As

Publication number Publication date
CO6470866A2 (es) 2012-06-29
US20100331386A1 (en) 2010-12-30
JP2012532107A (ja) 2012-12-13
CN104650106A (zh) 2015-05-27
TW201105677A (en) 2011-02-16
HRP20160732T1 (hr) 2016-07-15
US8450358B2 (en) 2013-05-28
IL217285A0 (en) 2012-02-29
SI2448943T1 (sl) 2016-07-29
TN2011000664A1 (en) 2013-05-24
PL2789617T3 (pl) 2017-02-28
ES2600160T3 (es) 2017-02-07
PL2448943T3 (pl) 2016-09-30
US20150025121A1 (en) 2015-01-22
AU2010266549B2 (en) 2015-06-25
CA2764878A1 (fr) 2011-01-06
PH12015502323A1 (en) 2019-08-19
EP2448943A1 (fr) 2012-05-09
ES2578779T3 (es) 2016-08-01
DK2448943T3 (en) 2016-07-04
US20130072537A1 (en) 2013-03-21
AU2010266549A1 (en) 2012-01-19
NZ596903A (en) 2014-04-30
RU2535667C2 (ru) 2014-12-20
EP3156407A1 (fr) 2017-04-19
CN102471347A (zh) 2012-05-23
EP2789617A1 (fr) 2014-10-15
US9480677B2 (en) 2016-11-01
CA2764878C (fr) 2018-08-07
MX2012000028A (es) 2012-01-30
US20170073351A1 (en) 2017-03-16
HK1203192A1 (en) 2015-10-23
HUE029658T2 (en) 2017-03-28
IL241985A0 (en) 2015-11-30
AR077252A1 (es) 2011-08-10
BRPI1012129A2 (pt) 2016-03-29
WO2011002708A1 (fr) 2011-01-06
KR20120101980A (ko) 2012-09-17
IL250314A0 (en) 2017-03-30
RU2012102896A (ru) 2013-08-10
EP2789617B1 (fr) 2016-08-17
SMT201600203B (it) 2016-08-31
SG176307A1 (en) 2012-01-30
ECSP11011512A (es) 2012-01-31
IL241985A (en) 2017-02-28
CN102471347B (zh) 2015-07-29
MY159099A (en) 2016-12-15
CL2011003335A1 (es) 2012-05-25
JP2017002085A (ja) 2017-01-05
HK1168854A1 (zh) 2013-01-11
HRP20110946A2 (hr) 2012-01-31
EP2448943B1 (fr) 2016-03-30
PE20120413A1 (es) 2012-05-13
JP2015038153A (ja) 2015-02-26
ZA201108960B (en) 2013-03-27
IL217285A (en) 2016-09-29
KR101751378B1 (ko) 2017-06-28
CY1117776T1 (el) 2017-05-17
TWI465452B (zh) 2014-12-21
PE20160216A1 (es) 2016-05-11
PT2448943T (pt) 2016-07-12
PH12011502619A1 (en) 2021-06-23
US8883840B2 (en) 2014-11-11
MX342298B (es) 2016-09-23

Similar Documents

Publication Publication Date Title
MA33552B1 (fr) Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu&#39;agents thérapeutiques
MA56508B1 (fr) Inhibiteur de l&#39;egfr pour le traitement du cancer
MA44721B1 (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA47102B1 (fr) Dérivés de pyrane en tant qu&#39;inhibiteurs de cyp11a1 (cytochrome p450 monooxygénase 11a1)
MA52486B1 (fr) Pyridazinones utilisés en tant qu&#39;inhibiteurs de parp7
MA43169B1 (fr) Composés héterocycliques en tant qu&#39; inhibiteurs pi3k-gamma
GT200500102A (es) Compuestos de aril-o-heteroarilamida ortosustituidos
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA33745B1 (fr) Piperidines substituees qui accroissent l&#39;activite de p53, et utilisation de ces composes
MA30607B1 (fr) N-phenylmethyl -5-oxo-proline-2-amides substitues tenant lieu d&#39;antagonistes du recepteur p2x7 et procedes d&#39;utilisation
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA51669B1 (fr) Modulateurs de tmem16a
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA35576B1 (fr) Nouveaux composés
MA35275B1 (fr) Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a
MA54386B1 (fr) Modulateurs de trex1
EA201000046A1 (ru) Замещенные имидазогетероциклы
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA49127B1 (fr) Dérivés d&#39;indole n-substitués
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA39983B1 (fr) Dérivés de carboxamide
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية
MA38410B1 (fr) Composés d&#39;azétidinyloxyphénylpyrrolidine
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci